Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Inclusion Criteria:

- Between 18 and 65 years of age.

- Healthy.

- Subject is a nonsmoker.

- Subject's body mass index (BMI) is >=18 kilogram/meter square (kg/m^2) and <=30
kg/m^2

- Male or

- Female

Exclusion Criteria:

- Alanine aminotransferase (ALT) >1.5 x upper limit of normal range (ULN)

- Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is
fractionated and direct bilirubin <35 percent [%]).

- Current or chronic history of liver disease, or known hepatic or biliary
abnormalities

- QT interval corrected for heart rate according to Fridericia's formula (QTcF) > 450
millisecond (msec).

- Systolic blood pressure is >=140 millimeter of mercury (mmHg) at Screening;

- Diastolic blood pressure is >=90 mmHg at Screening;

- Heart rate is >100 beats/min at Screening.

- estimated glomerular filtration rate (eGFR) <=80 milliliter per minute per 1.73 meter
square (mL/min/1.73 m^2) (calculated using the Chronic Kidney Disease Epidemiology
Collaboration [CKD-EPI] formula) at Screening.

- Fasting triglyceride level >300 milligram per deciliter (mg/dL) at Screening.

- History of significant cardiovascular or pulmonary dysfunction prior to Screening.

- History of thyroid dysfunction or an abnormal (i.e., outside the normal reference
range) thyroid function test assessed by thyroid stimulating hormone at Screening.

- History of gastrointestinal surgery that could influence gastric emptying (e.g.,
gastrectomy, gastric bypass).

- History of pancreatitis.

- Personal or family history of multiple endocrine neoplasia type 2.

- Personal or family history of medullary carcinoma of the thyroid.

- Unable to refrain from the use of prescription or non-prescription drugs, including
vitamins, herbal and dietary supplements (including St John's Wort) within 7 days.

- History of regular alcohol consumption within 6 months of the study.

- Urinary cotinine levels indicative of smoking or history or regular use of tobacco-
or nicotine-containing products within 3 months prior to screening.

- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy.

- Subject has previously received any GLP-1 mimetic compound (eg., exenatide,
liraglutide, lixisenatide, dulaglutide).

- Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
result at screening or within 3 months prior to first dose of study treatment.

- A positive pre-study drug/alcohol screen.

- A positive test for human immunodeficiency virus (HIV) antibody.

- Subject has donated blood in excess of 500 mL within 56 days prior to dosing or
intention of donating in the month after completing the study.

- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).

- Exposure to more than 4 new chemical entities within 12 months prior to the first
dosing day